Lemerond Nicole 4

What Happened

• Nicole Lemerond, a director of MediciNova, was granted 44,500 derivative shares (recorded as an award) on 2026-06-23. The filing reports an acquisition price of $0, indicating this is a compensation grant (an option/award), not an open-market purchase.

Key Details

• Transaction date: 2026-06-23; Form 4 filed: 2026-06-25 (timely filing).
• Transaction code: A (award/grant/acquisition of derivative securities).
• Shares/derivatives granted: 44,500; reported acquisition price: $0.
• Vesting: The option vests in four equal installments on 2026-09-30, 2026-12-31, 2027-03-31 and 2027-06-30, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided excerpt.
• No sale or immediate exercise reported — this is an awarded derivative that vests over time.

Context

• This grant appears to be director compensation (an option/award) rather than a market purchase or sale. Such awards are common for board members and tie future value to continued service and company performance. Because no cash purchase or sale occurred and the grant vests over time, it should not be interpreted as an immediate bullish or bearish trade by the insider.